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CHAPTER 1 Introduction
Irinotecan was approved by the FDA as a second-line therapy for metastatic colon or rectal
cancer in 1996. It is derived from the plant alkaloid camptothecin (CPT) and specifically inhibits
eukaryotic DNA enzyme topoisomerase I. However, one of the leading side effects of irinotecan
is severe diarrhea. After oral administration, irinotecan is metabolized into SN-38G in the liver,
then SN-38G is excreted to the intestinal tract and deconjugated back to SN-38 by intestinal
bacterial β-glucuronidase. The free SN-38 in the gut leads to the delayed diarrhea by damaging the
intestinal mucosa. Therefore, selectively inhibiting the bacterial β-glucuronidase has become a
promising strategy to alleviate irinotecan-induced delayed diarrhea. The purpose of this project is
to explore more potent and higher selective inhibitors of bacterial β-glucuronidase from noni fruits,
aiming to alleviate the irinotecan-induced delayed diarrhea with minimized side effects.
1.1.

Irinotecan and Delayed Diarrhea
Camptothecin (CPT) was firstly discovered by Dr. Monroe E. Wall and Dr. Mansukh C.

Wani in the early 1960s (1). It is from Camptotheca acuminata Decne (family Nyssaceae), a tree
native to China (Figure 1). Earlier to the late 1950s, the Eastern Regional Research Laboratory
(ERRL) of USDA screened approximate 1000 ethanolic plant extracts for antitumor activities. The
Camptotheca extract was shown high antitumor activity by the CA-755 assay. Then, Dr. Wall and
Dr. Wani conducted antitumor assay-guided isolation on the extracts of the tree’s wood and bark.
The obtained monoterpene indole alkaloid (MIA), CPT (Figure 2), showed remarkable activity in
the life prolongation of mice treated with L1210 leukemia cells, with doses between 0.5 and 4.0
mg/kg. Based on this cytotoxic structure, a number of analogs were developed to fight off a variety
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of solid tumors, such as water insoluble 9-nitro- and 9-amino-CPT, and water-soluble analogs of
10-hydroxy-CPT that includes CPT-11 (Figure 2) and topotecan.

Figure 1. The trees, flowers and fruits of Camptotheca acuminata

By 1985, it was discovered that CPT and its analogues can specifically inhibit the
eukaryotic DNA enzyme topoisomerase I, which produces transient single-stranded DNA breaks
but doesn’t require ATP (2, 3). The levels of topoisomerase I are dramatically elevated in some
tumor cells, and also relatively high in quiescent and proliferating cells (4, 5). During the early Sphase of cell cycle, a cleavable complex that links topoisomerase and DNA is formed to unwind
the DNA double helix prior to the replication fork. CPT and its analogues act to irreversibly arrest
the replication fork by breaking the cleavable complex, which subsequently ceases DNA
replication and results in cell death (6, 7). The findings of this unique anticancer mechanism greatly
boosted the clinical trials of CPT and its analogues. Those compounds involved in a broad
spectrum of cancers, including leukemia, lymphoma, small and non-small cell lung cancer,
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colorectal cancer and cervical cancer (7). Among them, CPT-11, also called irinotecan, was
successfully developed as an anticancer drug. It was originally developed by Japanese
pharmaceutical companies Yakult Honsha and Daiichi, and firstly approved in Japan in 1994, then
in France in 1995. It was approved by the FDA of United States in 1996, as a second-line therapy
for metastatic colon or rectal cancer (1, 8).

Figure 2. The chemical structures of camptothecin (CPT, left) and irinotecan (CPT-11, right)

Up to date, irinotecan has been widely used to treat colorectal, lung and pancreatic cancers
(9). However, like other chemotherapeutic agents, such as fluorouracil and capecitabine of
fluoropyrimidines, one of the leading side effects of irinotecan is diarrhea, which is also called
chemotherapy-induced diarrhea (CID) (10). It has been reported that up to 88% of patients treated
irinotecan suffer from diarrhea, and 31% of these cases are grade 3 or 4 (Table 1) (11, 12).

4

Table 1. Common Terminology Criteria for Adverse Events for Diarrhea
Grade

Diarrhea Criteria

1

Increase of < 4 stools per day over baseline; mild increase in ostomy
output compared with baseline

2

Increase of 4-6 stools per day over baseline; moderate increase in ostomy
output compared with baseline
Increase of ≥7 stools per day over baseline; incontinence; hospitalization
indicated; severe increase in ostomy output compared with baseline;
limiting self-care activities of daily life
Life-threatening consequences; urgent intervention indicated
Death

3

4
5

Irinotecan may induce acute and delayed diarrhea (13). The acute diarrhea occurs
immediately after administration due to acute cholinergic properties. It is does-dependent and
could be rapidly and effectively treated by atropine (14). The delayed diarrhea happens more than
24 hours after drug administration. It is always a serious and dose-limiting adverse effect (14, 15).
In the liver, irinotecan is metabolized by carboxylesterases (CE) to produce SN-38, which exerts
100 to 1000-fold more potent cytotoxicity than irinotecan (16). Then, SN-38 is conjugated to the
inactive

and

non-toxic

SN-38-glucuronide

(SN-38G)

via

uridine

diphosphate-

glucuronosyltransferase 1A1 (UGT1A1). SN-38G is further excreted to the intestinal tract through
the bile duct. In the gut, SN-38G is deconjugated back to SN-38 by bacterial β-glucuronidase
(Figure 3). Even though the exact mechanisms are still in debate (13), this free SN-38 in the gut
can damage the intestinal mucosa, which is responsible for the delayed diarrhea (17, 18).
1.2.

Bacterial β-Glucuronidases and Inhibitors
The treatments of irinotecan-induced delayed diarrhea are still challenging. The National

Cancer Institute Common Toxicity Criteria are worldwide recognized guidelines for the
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assessment and management of chemotherapy-induced diarrhea, which were published in 2004
and updated in 2014 (19, 20). According to the guidelines, the delayed diarrhea could be managed
through dietary modification and using of antidiarrheal medicines based on specific mechanisms,
such as somatostatin analog octreotide, loperamide and deodorized tincture of opium. However,
these therapies may either worsen existing gastrointestinal symptoms, or cause other adverse
effects like uneven heartbeat, respiratory depression, neurotoxicity and seizures (21). Therefore,
more effective therapies for the delayed diarrhea are still urgently needed, and emerging new
methods have been investigated, including herbal extracts, phytochemicals and probiotics (12, 21).
β-Glucuronidases are members of glycosyl hydrolases that involve in the breakdown of
complex carbohydrates (22). Human β-glucuronidases exist in the lysosomes of most tissues and
body fluids (23). In the gut, brush border β-glucuronidases are mainly secreted by the bacteria of
Enterobacteriaceae family, including Salmonella, Klebsiella, Yersinia, Shigella, and especially
Escherichia coli. Gut bacterial β-glucuronidases assist the microbiota in harnessing available
glycosyl units as carbon sources, they are also the key mediators of intestinal toxicities associated
with anticancer drugs, including irinotecan (24).
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Figure 3. The mechanism of irinotecan-induced delayed diarrhea involving the production of
intestinal SN-38
As discussed above, the bacterial β-glucuronidase is essential for the generation of
intestinal SN-38. Alternative strategies targeting this enzyme have been paid increasing attention
along with the clinical application of irinotecan. They are aiming to alleviate the delayed diarrhea
by reducing the generation or inhibiting the activity of bacterial β-glucuronidase (Figure 3). Broadspectrum antibiotics have been used to reduce the production of bacterial β-glucuronidase by
killing intestinal bacteria, such as penicillin and streptomycin (25, 26), neomycin (26), and the
combination of cholestyramine and levofloxacin (27). However, these methods remove or
modulate the gut bacteria, which may disorder the normal microbial metabolism of carbohydrate,
vitamin and bile acids (28, 29), or increase the risks of pathogenic infection, such as Clostridium
difficile and Escherichia coli (30-32). As a result, the using of antibiotics may deteriorate the poor
health of patients who are suffering from the other side effects of chemotherapy (33).
It has initiated another active strategy to develop selective inhibitors against the enzyme
bacterial β-glucuronidase. Saccharo-1,4-lactone was firstly reported in 1952 for its competitive
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inhibition against β-glucuronidase from mouse liver (34, 35). In 2004, saccharic acid 1.4-lactone
was proven in animal experiment to be able to reduce mucosal damage induced by irinotecan,
however, exhibited a relatively low potency (36). The Kampo medicine (Hangeshashin-to) TJ-14
was also investigated for irinotecan-induced diarrhea (37, 38). Its protective effects were
tentatively attributed to the glucuronides, such as baicalin, wogonoside, luteolin-3′-glucuronide
and glycyrrhizin, due to their potential inhibition against β-glucuronidase (39, 40). But the exact
mechanisms of the Kampo extracts remain unclear. Since 2010, a group from the University of
North Carolina has published a series of research papers in this area. For the first time, they
reported inhibitors against β-glucuronidase from intestinal bacteria, instead of mammalian host.
Those compounds selectively inhibited bacterial β-glucuronidase with IC50 in the range of 0.284.8 µM (33, 41, 42). More importantly, they could reduce the irinotecan-induced gastrointestinal
damage, while without killing intestinal commensal bacteria and not toxic to the host intestinal
cells (11). Cheng et al. also reported pyrazolo[4,3-c] quinoline derivatives as specific inhibitors of
bacterial β-glucuronidase, without impacting the antitumor efficacy of irinotecan in mice (43, 44).
These inhibitors of bacterial β-glucuronidase have not achieved very potent and specific effects,
however, they represent a very promising orientation to develop supplemental or therapeutic
approaches to alleviate irinotecan-induced delayed diarrhea with minimized side effects.
1.3.

Specific Aims
In a preliminary experiment, we screened about 50 extracts for their inhibitory activities

against bacterial β-glucuronidase. Among them, an extract from noni fruits showed significant
inhibition on the enzyme. The purpose of this study is to further investigate the chemical
constituents of noni fruit extract and find out more potent and higher selective inhibitors against
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intestinal bacterial β-glucuronidase, aiming to alleviate the delayed diarrhea induced by irinotecan
administration, while with minimized side effects on the gastrointestinal tract. Therefore, the
specific aims of this project are as follows:
Aim 1: Extraction and Isolation (Chapter 2). To identify the chemical constituents of noni fruit
extract contributing to its inhibitory effect against bacterial β-glucuronidase, through
phytochemical extraction and isolation guided by bioactive assay.
Aim 2: Elucidation of Chemical Structures (Chapter 3). To elucidate chemical structures of
purified compounds using HRMS and 1D, 2D-NMR, and establish their absolute configurations
by comparing experimental and calculated ECD spectra.
Aim 3: Evaluation of Inhibitory Activities (Chapter 4). To measure inhibitory activities of
purified compounds against bacterial β-glucuronidase and digestive enzymes, evaluate their
inhibitory selectivity and intestinal adverse effects.
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CHAPTER 2 Isolation of Bioactive Compounds from Noni Fruits
Natural products are chemical substances or compounds isolated from living organism,
including plants, animals, fungi and microorganisms (45, 46). They are produced by the primary
or secondary metabolisms of organism. Primary metabolites are essential organic molecules for
the growth, development and reproduction of organism, such as nucleic acids, amino acids, fatty
acids and sugars. They are necessary building blocks to make life sustaining macromolecules
including DNA, proteins, lipids and carbohydrates. Secondary metabolites are not directly
involved in these essential processes, but they have ecological function that increase the
competitiveness of the organism to deal with very complicated and varied environment. They are
much more organism-dependent, and present great diversities in chemical structures and biological
functions. Such as flavonoids, phenolics, tannins and alkaloids, they have lots of structural
subtypes and are among the most bioactive compounds (47). Therefore, natural products of
secondary metabolites have been widely studied and developed for the application in food, spices,
traditional and modern medicines (48, 49). Like antibacterial drug penicillins from Penicillium
chrysogenum, opioid analgesic drug morphine from Papaver somniferum, and artemisinin
(qinghaosu) against Plasmodium falciparum malaria, natural products contribute greatly to the
history and landscape of new molecular entities (NMEs) (50). By the end of 2013, over one-third
(38%) of NMEs approved by U.S. Food and Drug Administration (FDA) are natural products or
their derivatives (51).
In our preliminary experiment, the bioactive extract used was also a mixture of secondary
metabolites from noni fruits. Therefore, the first priority of this project was to isolate the mixture
and obtain the purified compounds that contribute to the inhibitory activity against bacterial βglucuronidase.

10

2.1.

Introduction of Noni (Morinda citrifolia)
Morinda citrifolia L. (Rubiaceae) (Figure 4) is a small evergreen tree that is originated in

South Asia, but now is widely distributed across the tropical countries of the world, including
Polynesia, Northeastern Australia and the Caribbean (52). The most popular name “noni” is from
Hawaiian and Tahitian islands (53), whereas it is called Indian mulberry in India, mengkudu in
Malaysians and painkiller bush in the Caribbean (54), and the fruits are also known as cheese fruit
in Australia (55).

Figure 4. Fruits and flowers of Noni (Morinda citrifolia)

All parts of noni have been traditionally used for medicinal purposes, including the roots,
bark, leaves, seeds and fruits (52). Modern research on noni might be incentivized by the report
from the Pacific Tropical Garden Bulletin in 1985, which suggested a number of potential health
benefits for noni juice, such as treating high blood pressure, menstrual cramps, arthritis and many
others (55, 56). Since the 1990s, noni has become a popular dietary supplement in the USA (57).
The leaves and fruits could be sold as capsules, teas and juice. In particular, the noni fruit juice is

11

the predominant form in the market, and it could be pasteurized, fermented, or flavored by other
fruit juice to make the product more palatable (58). The noni fruit juice was approved by the
European commission in 2003 as well, and the use of noni has been broadly available in stores and
on the Internet (52).
2.1.1. Nutritional content and chemical constituents of noni
Nutritional content of M. citrifolia have been evaluated for health utilization. The leaves
were considered as an abundant source of carotenoids by Aalbersberg et al. (59). Peerzada et al.
found that noni fruits from Australia contain up to 2012 mg of potassium and 158 mg of vitamin
C per 100 g of dry weight (60). The noni fruit juice was also shown to possess relatively high
levels of potassium (30-150 ppm) and vitamin C (30-155 mg/kg) (61). Bui et al. analyzed the
saccharide content of noni fruits collected in Vietnam, it was found that the monosaccharides were
mostly galactose, arabinose, rhamnose and galacturonic acid, while polysaccharides were mainly
pectic polysaccharides, such as arabinan, pectins homogalacturonan, and type Ⅰ and Ⅱ
arabinogalactans (62).
The earliest research on chemical constituents of M. citrifolia could be traced back to the
investigation on noni roots, heartwood and cell culture, which were reported by Simonsen et al. in
1918 and 1920 (63, 64). After 50 years of silence, the phytochemical studies of these parts of noni,
and also seeds and flowers, emerged again during 1970s and 1980s (52). Since 1990s, the
phytochemical investigation on noni have been focused on the leaves and fruits (52). Generally,
the roots were found predominated by anthraquinones and anthraquinone glycosides (65), while
some iridoids, triterpenes and flavonoids were isolated from leaves (66). The plant cell cultures
were studied for their abilities to synthesize anthraquinoid pigments, and the focus on fruits came
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along with the commercial application of fruit juice as nutritional supplement (55). Up to date,
more than 200 chemical constituents have been reported from different parts of M. citrifolia,
including fatty acid glycosides, alcohol glycosides, iridoids and iridoid glycosides, lignans,
neolignans, anthraquinones and anthraquinone glycosides, flavonoids, phenylpropanoids,
triterpenoids and others (52, 55, 67). Their chemical structures were primarily identified by nuclear
magnetic resonance (NMR) spectroscopy and mass spectrometry (52).
2.1.2. Biological activities and safety of noni
The biological activities of both extracts and pure compounds of M. citrifolia have been
comprehensively evaluated in vitro and in vivo. The investigated parts include the leaves, roots,
seeds, and particularly the fruits (52, 55). Their pharmacological activities mainly involve in antimicrobial (68), anti-fungus (69), anti-virus (70), anti-oxidation (71), anti-inflammation (72), antiobesity (73), anti-diabetes (74), anti-arthritic (75), anti-tubercular (76), anti-pigmentation (77),
analgesic (78), and so on. Especially, the anticancer effects of M. citrifolia have attracted relative
more attention (79). The juice or extracts from noni fruits have been shown antiproliferative effects
against various tumor cells (80), reducing mammary tumor growth in mice (81), inducing
apoptosis in human cervical cancer cells and on the Ehrlich ascites tumor in Balb‐c mice (82, 83).
Pure compounds isolated from M. citrifolia proved to contribute to the overall anti-tumor activities
of noni extracts. Masuda et al. revealed that the two lignans, 3,3'-bisdemethylpinoresinol and
americanin A, were active constituents of noni seeds to inhibit melanogenesis in murine B16
melanoma cells (84). Two glycosides from noni fruit juice could inhibit AP-1 transactivation and
cell transformation in the mouse epidermal JB6 cell line (85). The anthraquinones from noni roots
showed significant inhibition against human lung and colon cancer cells (86, 87). An
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polysaccharide‐rich substance from noni fruit juice was also found having antitumor activity (88,
89).
It is worth noting that several clinical trials have been conducted for M. citrifolia (79). In
a randomized, double blinded and placebo-controlled trial, Prapaitrakool et al. showed that an
extract from M. citrifolia Linn. fruits effectively reduced the incidence of early postoperative
nausea (0-6 h) from 80% to 48% (P = 0.04), at the dose level of 600 mg and taken orally 1 hour
before surgery (90). In a Phase Ⅰ clinical trial aiming to determine noni dose for patients with
advanced cancer, Issell et al. suggested that a dose of four capsules four times per day (8 g) could
be appropriate for Phase Ⅱ trial in terms of quality of life measures (91). Noni has been used to
treat women with primary dysmenorrhea, but show no reduction effects on menstrual pain or
bleeding comparing to placebo (72). A combination of noni powder and anti-rheumatism therapy
showed effect to treat a case of psoriasis (92), another noni supplements combined with calorie
restriction and exercise interventions resulted in body weight loss and fat mass decrease for
overweight participants (73). However, the biological effects and contribution of noni were not
clarified in these combination studies, which need to be verified by further experiment.
A number of animal studies have indicated that noni administration are nontoxic to the rats
(93, 94). However, several cases of plausible toxicity have been reported for human who consumed
noni fruit juice (52). The elevated potassium levels were reported for a patient with chronic renal
insufficiency, but lacking detailed information on how much noni juice the patient took (95). Since
recommended dose of 1-3 oz per day would not cause hyperkalaemia, it is necessary to confirmed
whether the patient consumed a does more than recommendation (52). Another concern of noni
juice consumption is hepatotoxicity. Several patients from Austria and Germany demonstrated
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significant increasing in liver enzymes when taking noni juice, such as transaminases and lactate
dehydrogenase, and the levels of these liver enzymes returned back to normal levels after
interruption of noni juice intake (96-98). However, most of these patients were simultaneously
taking other herbs or medicines, the observed hepatotoxicity could not be directly linked with noni
juice without further evidences. A possible correlation between anthraquinones and hepatotoxicity
were suggested, however, the content of this constitutes was relatively high in noni roots, while
extremely low in noni fruits (55). Thus, it is not reasonable to deduce the toxicity of noni fruit
juice by anthraquinones. On the contrast, West et al. listed dietary utilization of noni and
summarized previous animal and human studies on noni, which gave a general conclusion that
noni is safe for dietary supplementation (93).
2.2.

Isolation and Purification
For the isolation of natural products, the normally used methods include extraction,

precipitation, adsorption, and especially chromatography (46). Each chromatographic method
consists of a stationary phase that doesn’t move and a mobile phase that does move (99, 100). The
mobile phase can be organic solvents, water or gas, which carries the mixture of sample to go
through the stationary phase. During the process, different compounds interact differently with the
two phases, and move forward with different velocities, which result in different retention
properties and chromatographic separation. Chromatographic methods could be divided into many
subtypes in terms of separation mechanism, phase condition and shape of chromatographic bed
(Table 2). Of which, the thin layer chromatography (TLC) is often used to predict or evaluate
separation effects, while column chromatography is primarily utilized to implement the practical
isolation of natural products due to its multiple functions and flexible application (101). Normally
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used methods of column chromatography include normal phase (silica gel), reverse phase (ODS,
C18), size exclusion (Sephadex LH-20) and so on. In order to obtain finer separation, the specific
stationary materials, mobile phase solvents and column size should be carefully optimized based
on the physical and chemical characteristics of target samples. It is worth noting that the semipreparative HPLC system combines high-efficient separation, on-line detection and analysis, and
even automatic sample collector together, which make it a widely used powerful technique for the
separation of samples that are difficult to be isolated by normal methods (analogues) and
compounds with small amounts (about 5 mg or less) (102).
Table 2. Classification of chromatography used for the isolation of natural products
Technique
paper chromatography (PC)

Format
planar

Stationary Phase
paper (cellulose)

thin-lay chromatography
(TLC)

planar

liquid chromatography (LC):
open column, mediapressure, high-performance
liquid chromatography
(HPLC)
gas chromatography (GC):
gas-liquid
gas-solid

column

silica, cellulose, ionexchange resin,
controlled porosity solid
solid or bonded phase,
controlled porosity
solid, ion-exchange
resin

column
column

liquid
solid

Mobile Phase
liquid

liquid

liquid

gas
gas

Separation Mechanism
partition (adsorption,
ion-exchange, sizeexclusion)
adsorption (partition,
ion-exchange, sizeexclusion)
modified partition
(adsorption), sizeexclusion, ion-change,
selective adsorption

adsorption
partition

2.2.1. Equipment and materials
In this study, semi-preparative HPLC was carried out on a Hitachi LaChrom Elite liquid
chromatograph system (Tokyo, Japan) equipped with L-2130 pump and L-2455 detector, and a
Waters XBridge BEH300 Prep C18 column (250 mm × 19 mm i.d., 10 μm; Milford, MA, USA).
Diaion HP20 adsorbent resin (highly porous type, ≥ 250 μm; Alfa Aesar, Ward Hill, MA, USA),
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silica gel (40-60 μm, 60 A; Acros Organics, Morris Plains, NJ, USA), and Sephadex LH-20 (GE
Healthcare, Uppsala, Sweden) were used for column chromatography fractionation.
Noni fruit powder was purchased from Starwest Botanicals, Inc. (Sacramento, CA, USA)
with lot numbers 58868 and 63285 (Figure 5). It was collected from India and identified as
Morinda citrifolia L. (Rubiaceae). The packages were stored in dark at 4 °C before use. A voucher
specimen (BS2015-029) was deposited in our laboratory, Department of Nutrition and Food
Science, Wayne State University.

Figure 5. Noni (Morinda citrifolia) fruit powder used in this study

2.2.2. Isolation procedures
The isolation of active compounds from noni fruit extract was guided by inhibitory assay
of bacterial β-glucuronidase (Figure 6). After each step of separation, only the bioactive fractions
were selected for further purification.
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Figure 6. The isolation process of bioactive compounds from Noni fruit powder

Specifically, noni fruit powder (13.2 kg) was extracted with 50% acetone/water twice (at
ratio of 10 L/kg and 8 L/kg, respectively) at room temperature with stirring. The combined extracts
were concentrated until acetone was completely removed, then the water phase was subjected to
separation over a HP-20 resin column (11 × 70 cm), and eluted with 0%, 30%, 50%, 70% and 100%
ethanol/water, sequentially. After being concentrated, 29 g of 70% ethanol/water extract (active
fraction) was further fractionated via silica gel column chromatography (7 × 46 cm), and eluted
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with CH2Cl2-MeOH (1:0, 20:1, 10:1, 6:1, 4:1, 1:1 and 0:1, v/v), to yield five sub-fractions (F-1 to
5). Active fraction F-3 (10 g) was then separated on a silica gel containing column with CH2Cl2MeOH (20:1, 10:1, 5:1, and 2:1, v/v) to obtain four sub-fractions. Active subfraction F-3-2 (2.7 g)
was further purified by a Sephadex LH-20 column chromatography (CH2Cl2-MeOH, 1:1, v/v) to
afford two main sub-fractions. Active fraction F-3-2-2 (800 mg) was purified by semi-preparative
HPLC (CH3CN-H2O, 1:20, v/v; 4 mL/min; detector wavelength at 230 nm), to obtain four purified
active compounds, 1 (31.93 min, 12 mg), 2 (48.19 min, 11 mg), 3 (69.50 min, 33 mg), and 4 (83.42
min, 87 mg) (Figure 7).

Figure 7. Semi-preparative HPLC chromatogram of fraction F-3-2-2
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CHAPTER 3 Elucidation of Chemical Structures
Chemical structure refers to the spatial arrangement of atoms in a molecule and the
chemical bonds that connect atoms together. Carbon and hydrogen are the elementary atoms of
organic compounds or natural products. Most of natural products also contain oxygen, and some
may include nitrogen, phosphorous, sulfur or the halogens. These atoms are mainly linked by
covalence bonds that share electron pairs in the forms of single, double or triple bonds. In the
history, the chemical structures of natural products could not be described until the advent of
structural theory based on the frameworks of Kekulé (1857), Couper (1858) and Butlerov (1859),
and the foundation of stereochemistry by Le Bel (1874) and van’t Hoff (1875) (103).
Early procedure of structural elucidation is very complicated (46). It was often started with
the measurement of sharp melting point to confirm the purity, and elemental analysis to decide
molecular formula. It was followed by a combination of derivatization and degradation reactions
to deduce functional groups and fragments. Eventually, the proposed structure needs to be
validated by known chemical synthesis. Consequently, a large amount of sample (grams) was
required for destructive reactions, and it always took several or even tens of years to figure out a
specific structure. For example, the structures of morphine and strychnine were determined 118
and 127 years after they were firstly isolated, respectively (104, 105). Until 1960s, structural
elucidation was developed into a new era that is dominated by spectroscopic techniques and X-ray
crystallography (103). Up to date, frequently used spectroscopic methods include nuclear magnetic
resonance (NMR), which contains 1H-, 13C-, and 2D-NMR, mass spectrometry (MS), ultraviolet
(UV) and infrared (IR). In addition, a lot of new methods have been developed and applied in this
area, such as 3D-NMR, solid-state NMR and computer-assisted structure elucidation (106, 107).
Combination of these techniques greatly simplified elucidation process. The time used could be
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reduced to several days or even minutes, sample amount required could be several milligrams, and
it is much easier to solve the structures of complicated natural products (108).
Absolute configuration is a concept of stereochemistry, it refers to the spatial arrangement
of the atoms of a chiral molecular entity, and could be described in R (Rectus) or S (Sinister)
(Figure 8) (109). Theoretically, if a chiral molecule contains number n (≥ 1) of chiral center atom(s)
(usually carbon), it can exist in any of the 2n of absolute configurations. In other words, it has 2n-1
pair(s) of possible enantiomers, and each pair of enantiomers has mirror-image structures.
However, as natural products of living organisms, all discovered primary metabolites (L-amino
acids, nucleotides and monosaccharides) and about 80% of known secondary metabolites are chiral
non-racemic or asymmetric enantiopure molecules (110). Besides, it is found that two enantiomers
of a chiral molecule always possess totally different biological activities and pharmacological
behaviors, which may due to their biological receptors of organisms that are already chiral in
structures (111). Among the new molecular entities approved by the FDA, chiral drugs have
increased from 30-40% in the 1990s to over 60% of in the 2000s (112). Therefore, determining
the absolute configuration of a chiral molecule has become an important, but also challenging area
in the chemistry of natural products (110, 113).

Figure 8. Description of absolute configurations for a pair of enantiomers, A, B, C, D represent
four functional groups with priority from high to low.
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Single crystal X-ray diffraction analysis has been considered the most accurate and
important method to determine absolute configuration. However, the measurement requires high
quality of crystal, which limits its application for many natural products that are difficult to culture
crystal. The modified Mosher’s NMR method is another powerful tool to decide absolute
configuration. But it is not easy to find suitable functional groups (normally OH and NH2) in many
molecules to conduct chiral derivatization. Chiroptical methods are based on the optical
interactions between chiral non-racemic compounds and the right and left circularly polarized light.
Currently, the primary chiroptical spectroscopy includes optical rotation (OR), optical rotatory
dispersion (ORD), electronic circular dichroism (ECD) and vibrational circular dichroism (VCD).
Especially, ECD and VCD have been more frequently used for determining absolute
configurations of natural products, due to their less demand on structural properties, sample
amount and status (114). In practical use, absolute configuration of a specific compound is
established by comparing its experimental circular dichroism (CD) spectrum to the CD spectra of
appropriate analogues with known absolute configuration. However, it is hard to find comparable
analogues for most of novel natural products. In this case, calculated CD spectra have become a
credible alternative along with the development of computational chemistry (115).
In this study, the structures of four purified compounds were elucidated through the
combination of HRESIMS, MNR and UV. Their absolute configurations were established with the
assistance of ECD calculation, because of limited amounts, difficulty of culturing single crystal
and lack of comparable known CD spectra.
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3.1.

Spectroscopic Data Acquisition
The optical rotations were measured in MeOH on an Autopol Ⅲ automatic polarimeter

(Rudolph Research Analytical, Hackettstown, NJ, USA) with a sodium lamp operating at 589 nm.
ECD spectra in solvent methanol were recorded on a JASCO J-815 spectrometer (Tokyo, Japan).
NMR spectra were obtained from Varian VNMRS-500 MHz (Palo Alto, CA, USA) and Agilent
DD2-600 MHz (for optimized HMBC spectra; Santa Clara, CA, USA) spectrometers, with δ in
ppm related to TMS, and J in Hz. HRESIMS analyses were performed on Thermo Scientific LTQ
Orbitrap XL Mass Spectrometer (San Jose, CA, USA).
(7S,8S,7'R,8'R)-Isoamericanol B (1). Brown amorphous powder; [α]22D - 8.0 (c 0.05, MeOH);
UV (MeOH) λmax (log ε) 206 (5.01), 230 (sh) (4.52), 270 (4.12), 287 (sh) (4.05), 305 (sh) (3.57),
315 (sh) (3.36) nm; ECD (MeOH) λmax (Δε) 205 (+ 2.58), 211 (- 7.49), 218 (+ 0.36), 226 (- 1.31),
241 (+ 0.14), 288 (- 1.50) nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table
3; HRESIMS m/z 493.1491 [M - H]- (calcd for C27H25O9, 493.1493, Figure A1).
Americanol B (2). Brown amorphous powder; [α]22D + 2.0 (c 0.05, MeOH); UV (MeOH)
λmax (log ε) 206 (5.00), 230 (sh) (4.54), 270 (4.16), 287 (sh) (4.10), 305 (sh) (3.65), 315 (sh) (3.43)
nm; ECD (MeOH) λmax (Δε) 198 (+ 1.53), 206 (- 14.7), 219 (- 0.29), 225 (- 1.51), 245 (- 0.09), 288
(- 1.96) nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 3; HRESIMS m/z
493.1486 [M - H]- (calcd for C27H25O9, 493.1493, Figure A2).
Moricitrin A (3). Brown amorphous powder; [α]22D + 2.0 (c 0.05, MeOH); UV (MeOH) λmax
(log ε) 206 (5.06), 230 (sh) (4.40), 283 (4.00), 310 (sh) (2.97) nm; ECD (MeOH) λmax (Δε) 195 (+
8.69), 200 (- 11.57), 206 (- 5.06), 209 (- 5.80), 232 (+ 0.34), 247 (- 2.07), 257 (- 0.67), 280 (- 2.58)
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nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 3; HRESIMS m/z 657.1952
[M - H]- (calcd for C36H33O12, 657.1967, Figure A3).
Moricitrin B (4). Brown amorphous powder; [α]22D - 8.0 (c 0.05, MeOH); UV (MeOH) λmax
(log ε) 206 (5.06), 230 (sh) (4.42), 283 (4.03), 310 (sh) (3.08) nm; ECD (MeOH) λmax (Δε) 198 (+
10.64), 210 (- 6.92), 221 (- 0.61), 229 (- 1.30), 233 (- 0.17), 239 (- 1.42), 245 (- 0.53), 283 (- 2.47)
nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 3; HRESIMS m/z 657.1954
[M - H]- (calcd for C36H33O12, 657.1967, Figure A4).
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Table 3. 1H and 13C NMR Spectroscopic Data of Compounds 1-4 in CD3OD
position
1
2
3
4
5
6
7
8
9

δC, type
129.4, C
115.5, CH
146.6, C
147.1, C
116.3, CH
120.4, CH
77.6, CH
79.9, CH
62.0, CH2

1'
2'
3'
4'
5'
6'
7'
8'
9'

131.3, C
117.2, CH
145.4, C
145.4, C
118.1, CH
121.8, CH
77.3, CH
79.9, CH
62.0, CH2

1"
2"
3"
4"
5"
6"

132.0, C
115.5, CH
144.5, C
145.1, C
117.9, CH
120.9, CH

7"

131.3, CH

8"
9"

1
δH (J in Hz)
6.87, d (2.3)

6.81, m
6.78, m
4.84, d (8.2)
4.03, m
3.49, m
3.70, m

7.01, m

7.02, m
6.97, m
4.90, m
4.03, m
3.50, m
3.70, m
6.97, d (2.3)

6.90, m
6.92, m

δC, type
129.4, C
115.5, CH
146.6, C
147.2, C
116.4, CH
120.4, CH
77.6, CH
79.8, CH
62.1, CH2

131.3, C
117.2, CH
145.8, C
145.0, C
118.1, CH
121.6, CH
77.3, CH
79.8, CH
62.1, CH2
132.2, C
115.5, CH
144.8, C
144.8, C
118.0, CH
120.8, CH
131.3, CH

128.2, CH

6.49, d
(15.3)
6.21, m

63.7, CH2

4.19, m

63.8, CH2

128.2, CH

2
δH (J in Hz)
6.87, d (2.1)

6.82, m
6.77, m
4.83, d (8.1)
4.01, m
3.50, m
3.70, m

7.06, m

6.93, m
6.93, m
4.91, m
4.01, m
3.50, m
3.70, m
7.03, d (1.8)

6.87, m
6.91, m
6.51, d
(16.0)
6.22, dt
(16.0, 5.8)
4.20, m

δC, type
135.5, C
115.8, CH
145.2, C
144.4, C
117.9, CH
120.3, CH
87.0, CH
55.3, CH
72.7, CH2

135.5, C
115.8, CH
145.2, C
144.4, C
117.9, CH
120.3, CH
87.0, CH
55.3, CH
72.7, CH2
129.5, C
115.6, CH
146.6, C
147.1, C
116.4, CH
120.4, CH

3
δH (J in Hz)
6.89, m

6.91, d (8.3)
6.85, m
4.66, brs
3.04, brs
3.79, m
4.18, m

6.89, m

6.91, d (8.3)
6.85, m
4.66, brs
3.04, brs
3.79, m
4.18, m
6.85, m

77.6, CH

6.80, d (8.0)
6.74, dd
(8.0, 2.0)
4.77, d (8.0)

79.9, CH
62.1, CH2

1'"
2'"
3'"
4'"
5'"
6'"

129.5, C
115.6, CH
146.6, C
147.1, C
116.4, CH
120.4, CH

7'"
8'"
9'"

77.6, CH
79.9, CH
62.1, CH2

δC, type
135.6, C
115.8, CH
144.4, C
144.8, C
118.0, CH
120.1, CH
87.0, CH
55.4, CH
72.7, CH2

135.6, C
115.8, CH
144.4, C
144.8, C
118.0, CH
120.1, CH
87.0, CH
55.4, CH
72.7, CH2
129.5, C
115.5, CH
146.6, C
147.1, C
116.3, CH
120.4, CH

4
δH (J in Hz)
6.96, m

6.92, d (8.3)
6.83, m
4.67, brs
3.06, brs
3.81, m
4.19, m

6.96, m

6.92, d (8.3)
6.83, m
4.67, brs
3.06, brs
3.81, m
4.19, m
6.84. m

6.79, m
6.74, m

77.6, CH

4.79, d (7.9)

3.97, m

79.9, CH

3.98, m

3.45, dd
(12.2, 4.5)
3.65, d
(12.2)

62.1, CH2

3.45, dd
(12.2, 4.5)
3.65, d
(12.2)

6.85, m

6.80, d (8.0)
6.74, dd
(8.0, 2.0)
4.77, d (8.0)
3.97, m
3.45, dd
(12.2, 4.5)
3.65, d
(12.2)

129.5, C
115.5, CH
146.6, C
147.1, C
116.3, CH
120.4, CH
77.6, CH
79.9, CH
62.1, CH2

6.84. m

6.79, m
6.74, m
4.79, d (7.9)
3.98, m
3.45, dd
(12.2, 4.5)
3.65, d
(12.2)
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3.2.

ECD Computation

3.2.1. Computational chemistry and its application in CD calculation
Computational chemistry is founded on the development of theoretical chemistry and
efficient computer programs (116). It can be used to calculate structures and properties of
molecules, such as relative energy, dipole moment, vibrational frequency, charge distribution,
reactivity and spectroscopic quantity. The aims of computational chemistry are to analyze
complicated experimental data, predict new reactions or molecules, or predict spectroscopies.
There are two types of methods to model molecular systems according to starting point theory.
One type is classical method based on the laws of classical physics, which treat atoms as spheres
and bonds as springs, while ignoring electronic distribution in molecules. Classical methods
primarily contain molecular mechanics (MM) and molecular dynamics (MD). They are
implemented through force fields that refer to functional forms and parameter sets of calculation.
Many force fields have been designed for different simulation purposes, such as AMBER and
CHSRMM for molecular dynamics of macromolecules, MM2 for conformational analysis, and
MMFF (Merck Molecular Force Field) for a broad range of molecules (117). Another type is
quantum chemistry methods based on quantum mechanics (QM), which describe electronic
distribution of molecules using Schrödinger’s equation. Complete solution of Schrödinger’s
equation can provide an exact description of electronic structure of a molecule. However, up to
data, the equation can only be exactly solved for hydrogen atom, but not for any other atomic or
molecular systems involving motions of three or more particles. Alternatively, approximate
solutions have been developed for practical application, which include ab initio methods (HartreeFock, MP2), semi-empirical methods (AM1, MNDO, PM3), and density-functional theory (DFT)
and its extension time-dependent DFT (TDDFT). A basis set is a set of functions used to carry out
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the calculation of Hartree-Fock (HF) or DFT. Commonly used basis sets include B3LYP, 6-31G,
6-311G, cc-pVDZ and so on (117).
Molecular mechanics (MM) is restricted to describe equilibrium structures and
conformations. It could be used to minimize energies, study molecular motions, and search stable
conformations. While quantum mechanics additionally provides information of non-equilibrium
forms, it is suitable to calculate molecular orbital energies, heat formation of a conformation,
dipole moment and transition-state geometries and energies (116, 118). Quantum mechanics has
more computing power than molecular mechanics, but it is more computational expensive (time)
and only limited to hundreds of atoms. Selection of specific methods is dependent on calculation
goals, and the trade-off between accuracy and computational expense.
The procedure of CD computation primarily consists of conformational analysis and DFT
or TDDFT calculation (117). Because of rotation about single bonds, a compound presents in
multiple conformers that are rapidly equilibrating. The population distributions of conformers are
determined by their relative free energies, a conformer with lower free energy is more stable and
has higher population. The interconversion rate between isomers are decided by energy barriers,
the higher barrier means lower interconversion rate. CD spectrum is sensitive to conformation, it
is a spectral combination of all conformers following Boltzmann distribution. Therefore, the first
step is searching for stable conformers with lower free energies that contribute the most to the
dynamic equilibrium, by molecular mechanics force fields. Obtained stable conformers could be
optimized using less expensive basis sets of DFT calculation. Then, each stable conformer is
calculated for CD spectrum. DFT methods is often used for VCD computation that involves ground
electronic state. However, UV and ECD are properties of excited electronic state, which need
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TDDFT method to calculate oscillator strength that simulate UV curve, and rotatory strength that
predict ECD curve (115). Since CD spectrum of a compound is experimentally measured in the
form of solution, the effects of solvent need to be taken into account for computation. Either
explicit or implicit solvation models could be utilized to simulate solvent effects. The implicit
solvation model treats solvent as a continuum medium, particularly the polarizable continuum
model (PCM) has been most commonly used for CD calculation (117).
3.2.2. ECD calculation of compounds 1-4
ECD and VCD are different in measuring mechanisms, application requirements and
calculation methods (Table 4) (119, 120). VCD spectrum doesn’t rely on the existence of
chromophore groups in a molecule and has a relatively broader spectrum range, which shows a
prospect of wide application. However, VCD is a relative young technique that the first
commercial instrument was introduced in 1997 (121), and usable theories of spectrum
interpretation have not been established. In addition, VCD measurement demand a relatively high
sample concentration (20-50 mg/mL) (110). These are still restrictions for VCD application
currently. While ECD has been used for more than five decades, there are plenty of practical
accumulation, and many semi-empirical rules and exciton chirality methods have been developed
to interpret ECD spectra (110). With the advantage of less requirement on sample amount, ECD
is still a frequently used tool for determining absolute configurations.
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Table 4. Comparison between ECD and VCD
ECD

VCD

Radiation

ultraviolet and visible light

infrared (IR) region

Induced Transition

electronic

vibrational

Sample Amount

1-10 µg/mL

20-50 mg/mL

Chromophore Group

needed

not necessary

Calculation

excitation state TDDFT

ground state DFT

Compounds 1-4 have relatively small amounts, but possess chromophore groups, which
makes ECD computation a feasible choice to determine their absolute configurations. Since each
compound has two pairs of possible enantiomers, and ECD spectra of paired enantiomers are
theoretically symmetric, only one enantiomer of each pair was calculated using quantummechanical methods (Table 5).
Table 5. Possible enantiomers of compounds 1-4
Calculated enantiomer
1a (7S, 8S, 7'R, 8'R)
1b (7R, 8R, 7'R, 8'R)

Paired enantiomer
1a' (7R, 8R, 7'S, 8'S)
1b' (7S, 8S, 7'S, 8'S)

2a (7S, 8S, 7'R, 8'R)
2b (7R, 8R, 7'R, 8'R)

2a' (7R, 8R, 7'S, 8'S)
2b' (7S, 8S, 7'S, 8'S)

3a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S)
3b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R)

3a' (7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R)
3b' (7R, 8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S)

4a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S)
4b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R)

4a' (7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R)
4b' (7R, 8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S)

In this investigation, conformational analysis was performed by CONFLEX 8 (Revision A,
Tokyo, Japan), DFT (density functional theory) geometry optimization and TDDFT (timedependent density functional theory) calculations were carried out with Gaussian 09 (Wallingford,

29

CT, USA), and the calculated UV and ECD spectra were plotted using SpecDis (Version 1.71,
Berlin, Germany) (115).

Figure 9. Determination of absolute configuration by ECD calculation

Specifically shown in Figure 9, force field MMFF94S was used for conformer searching
of each configuration, and energy window was set at 3 kcal/mol. The obtained stable conformers
with populations above 0.5% or 1.0% (Table 6) were optimized further by a DFT method at the
B3LYP/6-31G(d) level, with solvent effects of methanol included using a polarizable continuum
model (PCM) (122). Thereafter, the dominant conformers possessing relative energies less than
0.8 or 2.0 kcal/mol were selected (Table 6), and their TDDFT calculations were performed at the
APFD/6-311+g (2d, p) level with PCM (methanol) (123). The spectra obtained of the conformers
were averaged by SpecDis according to their Boltzmann distributions, which generate theoretical
ECD (Figure 14, 17, 20 and 23) and UV (Figure 10) spectra of each configuration. UV spectra
could be used to validate the method that also used to calculate ECD spectra.
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Table 6. Criteria of Conformer Selection for DFT Optimization and TDDFT Calculation of
Model Configurations of Compounds 1-4
configuration

conformer for DFT optimization

conformer for TDDFT calculation

(population, number)

(relative energy in kcal/mol, number)

1a

> 0.5%, 38

< 0.8, 17

1b

> 0.5%, 28

< 0.8, 13

2a

> 0.5%, 30

< 0.8, 16

2b

> 0.5%, 32

< 0.8, 21

3a

> 1.0%, 9

< 2.0, 2

3b

> 1.0%, 5

< 2.0, 3

4a

> 1.0%, 19

< 2.0, 18

4b

> 1.0%, 2

< 2.0, 1

Figure 10. Experimental (solid lines) and calculated (dashed lines) UV spectra of compounds 14 and their model structures
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3.3.

Structural Elucidation
The four compounds were elucidated as two sesquineolignans, (7S,8S,7'R,8'R)-

isoamericanol B (1) and americanol B (2), and two dineolignans, moricitrin A (3) and moricitrin
B (4) (Figure 11). Of which, compounds 2-4 are new structures, and the absolute configuration of
1 was assigned for the first time.

1 (= 1a, 7S, 8S, 7'R, 8'R)

3 (= 3a', 7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R)

2 (= 2a', 7R, 8R, 7'S, 8'S)

4 (= 4b', 7R, 8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S)

Figure 11. Chemical structures of compounds 1-4. a, a', b and b' represent model configurations
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3.3.1. (7S,8S,7'R,8'R)-Isoamericanol B
Compound 1 was obtained as brown amorphous powder with an optical rotation of [α]22D 8.0 (c 0.05, MeOH). Its molecular formula was determined as C27H26O9 by analyzing the
HRESIMS peak at m/z 493.1491 [M - H]- (calcd for 493.1493) and 1H and 13C NMR spectroscopic
data (Table 1). Compound 1 was identified as a known sesquineolignan, isoamericanol B1 or B2,
by further comparing its NMR data with the previously reported structures (124). The paired
signals at δ 144.5 (C-3") and 145.1(C-4") in the 13C NMR spectrum suggested an isoamericanoltype structure with an additional caffeoyl alcohol substitution. The isoamericanol-type moiety was
confirmed by the observation of a diagnostic correlation between H-9'b (δ 3.50) and C-4" after
optimizing the proton-carbon coupling constant of HMBC to 3 Hz (Figure 12). Two signals at δ
145.4 (C-3' and C-4') suggested that the additional hydroxymethyl group is located on the same
side of the molecule as C-4', and the dihydroxy-phenyl group is close to C-3'. The coupling
constant J7",8" = 15.3 Hz suggested an E-configuration at the double bond of C-7" and C-8". The
large coupling constant between H-7 and H-8 (J = 8.2 Hz) indicated a trans substitution at C-7 and
C-8 (125). All the signals of 1 were assigned with the assistance of HSQC, COSY and HMBC
NMR spectra.

Figure 12. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 1
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ECD spectra have been used extensively to establish the absolute configuration of natural
product structures based on relative configurations. However, ROESY correlations between H7/H-8 and H-7'/H-8' were not detectable in this investigation due to the long distances between
these two steric centers (6.7-8.0 Å, Figure 13), making it impossible to determine the relative
configurations of H-7 and H-8 based on the ROESY spectrum. This is consistent with the previous
report on elucidating the same type of compounds with this technique (124).

proton
H-7 to H-7'
H-7 to H-8'
H-8 to H-7'
H-8 to H-8'

distance
7.7 Å
6.7 Å
8.0 Å
7.8 Å

1
Figure 13. Distances between protons of steric centers for compounds 1 (energy minimized by
MM2 force field)

Theoretically, possible trans substitutions of H-7 and H-8 generate two pairs of
enantiomers, namely, 1a (7S, 8S, 7'R, 8'R) and 1a' (7R, 8R, 7'S, 8'S), 1b (7R, 8R, 7'R, 8'R) and 1b'
(7S, 8S, 7'S, 8'S). Within this small scope, it was hypothesized that each configuration possesses a
unique ECD spectrum. Hence, ECD spectra were measured to determine their relative and absolute
configurations simultaneously. The ECD spectra of 1a and 1b were calculated. As shown in Figure
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14, the experimental ECD spectrum matched best with 1a, suggesting that 1 has the same absolute
configuration as 1a (7S, 8S, 7'R, 8'R). Therefore, the structure of 1 was determined as (7"E)(7S,8S,7'R,8'R)-3,4,9,9',9"-pentahydroxy-7,3':7',3"-diepoxy-8,4':8',4"-bisoxysesquineolign-7"ene, namely, (7S,8S,7'R,8'R)-isoamericanol B. This represents the first time that the absolute
configuration of this compound has been established.

Figure 14. Experimental and calculated ECD spectra of compound 1 in MeOH, a and b
represent the model configurations of each compound

3.3.2. Americanol B
Compound 2 was purified as brown amorphous powder with an optical rotation of [α]22D +
2.0 (c 0.05, MeOH). Its molecular formula was determined as C27H26O9 by analyzing the
HRESIMS peak at m/z 493.1486 [M - H]- (calcd for 493.1493) and its 1H and 13C NMR data (Table
1). By comparing its NMR data to those of similar structures isoamericanol C1 or C2 (124), the
consistent signals at δC 145.8 (C-3') and 145.0 (C-4') supported a hydroxymethyl group being
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located on the same side of the molecule as C-3', and a dihydroxy-phenyl group being on the same
side as C-4'. However, different chemical shifts at δC 144.8 (C-3" and C-4") suggested a different
substitution for the hydroxypropenyl group in compound 2. Weak correlations from H-9' (δ 3.50)
and H-7' to the signals of δC 144.8 were observed in the HMBC spectrum with the proton-carbon
coupling constant optimized as 3 Hz (Figure 15), however, the signals at δC 144.8 were assigned
to both C-3" and C-4", thus, these correlations could not be used to distinguish the different
substitutions. Nevertheless, the characteristics of C-3" and C-4" were identical to those of reported
C-3' and C-4' in americanol A (53, 124, 126). Therefore, the hydroxypropenyl group was proposed
as being located on the same side of the molecule as C-8' in compound 2. The coupling constant
J7",8" = 16.0 Hz revealed an E-configuration at C-7" and C-8", J7,8 = 8.1 Hz suggested the trans
orientations of H-7 and H-8. All signals were assigned with the assistance of HSQC, COSY and
HMBC NMR spectra.

Figure 15. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 2

Compound 2 also has two pairs of trans enantiomers, 2a (7S, 8S, 7'R, 8'R) and 2a' (7R, 8R,
7'S, 8'S), and 2b (7R, 8R, 7'R, 8'R) and 2b' (7S, 8S, 7'S, 8'S), and the long distances between H7/H-8 and H-7'/H-8' (6.4-7.6 Å, Figure 16) restricted the use of ROESY spectrum for determining
its relative configuration.

36

proton
H-7 to H-7'
H-7 to H-8'
H-8 to H-7'
H-8 to H-8'

distance
6.4 Å
7.2 Å
6.5 Å
7.6 Å

2
Figure 16. Distances between protons of steric centers for compounds 2 (energy minimized by
MM2 force field)

The ECD spectra of 2a and 2b were calculated, and the experimental spectrum showed an
inversed pattern of Cotton effects to 2a (Figure 17). Hence, compound 2 was assigned with the
same configuration as 2a', and it was determined as a new sesquineolignan, (7"E)-(7R,8R,7'S,8'S)3,4,9,9',9"-pentahydroxy-7,4':7',4"-diepoxy-8,3':8',3"-bisoxysesquineolign-7"-ene,

and

named americanol B.

Figure 17. Experimental and calculated ECD spectra of compound 2 in MeOH, a and b
represent the model configurations of each compound

was
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3.3.3. Moricitrin A
Compound 3 was purified as brown amorphous powder with an optical rotation of [α]22D +
2.0 (c 0.05, MeOH). Its molecular formula was determined as C36H34O12 based on the HRESIMS
peak at m/z 657.1952 [M - H]- (calcd for 657.1967) and 1H and 13C NMR data (Table 1). It should
be noted that the 1H and

13

C NMR spectra only showed half of the total numbers of proton and

carbon atoms present, suggesting that the structure consists of two identical moieties. The

13

C

NMR spectrum presented typical signals of four C6C3 units, with each including six aromatic
carbons (δ 115-150) and three alkoxy carbons (δ 62-87), suggesting that compound 3 is a
dineolignan. The 13C NMR signals at δ 87.0 (C-7, 7'), 55.3 (C-8, 8') and 72.7 (C-9, 9') and their
corresponding 1H NMR signals at δ 4.66 (H-7, 7'), 3.04 (H-8, 8'), and 4.18 and 3.79 (H-9a, 9'a and
9b, 9'b) suggested a symmetric furofuran-type moiety (124). In turn, the 13C NMR signals at δ 77.6
(C-7", 7'"), 79.9 (C-8", 8'") and 62.1 (C-9", 9'"), and the 1H NMR signals at δ 4.77 (H-7", 7'"), 3.97
(H-8", 8'"), and 3.65 and 3.45 (H-9"a, 9'"a and 9"b, 9'"b) suggested a 1,4-benzodioxane-type unit to
be present. Collectively, the structure of compound 3 was established as having a 3, 3'bisdemethylpinoresinol skeleton with symmetrical additions of two phenylpropanoid groups to C3 and C-4, and C-3' and C-4', respectively. The chemical shifts at δC 145.2 (C-3, 3') and 144.4 (C4, 4') were consistent with the signals of C-3' and C-4' in isoprincepin (53, 124), suggesting that
the two dihydroxy-phenyl groups are located on the same side of the molecule as C-3 and C-3',
respectively. The locations of the dihydroxy-phenyl groups were confirmed based on the detected
HMBC correlations between H-7" and C-3, H-7'" and C-3', H-9"b (δ 3.45) and C-4, as well as H9'"b (δ 3.45) and C-4', after optimizing the proton-carbon coupling constant to 3 Hz (Figure 18).
All the signals were assigned with the assistance of the HSQC, COSY and HMBC NMR spectra.
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Figure 18. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 3

The large coupling constants of J7",8" (8.0 Hz) and J

7'",8'"

(8.0 Hz) suggested the trans

substitutions of H-7" and H-8", and H-7'" and H-8'" in compound 3. The ROESY correlations were
not detectable for establishing relative configurations due to the large distance from H-7" and H8" to H-7 and H-8, from H-7'" and H-8'" to H-7' and H-8' (6.2-7.1 Å, Figure 19).(124)

proton
H-7 to H-7"
H-7 to H-8"
H-8 to H-7"
H-8 to H-8"

distance
6.2 Å
6.7 Å
7.1 Å
6.3 Å

3
Figure 19. Distances between protons of steric centers for compounds 3 (energy minimized by
MM2 force field)

There are four theoretical configurations including 3a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S),
3a' (7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R), 3b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R) and 3b' (7R,
8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S). Among them, ECD spectra of 3a and 3b were simulated. The
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experimental results matched closely with the inverse Cotton effects of 3a (Figure 20), suggesting
that compound 3 shares the same configuration with 3a'. Therefore, its structure was established
as a new dineolignan, (7R,8S,7'R,8'S,7"R,8"R,7'"R,8'"R)-7,9':7',9:3,7":3',7'"-tetraepoxy-4,8":4',8'"bisoxy-8,8'-dineolignan-3",4",9",3'",4'",9'"-hexaol, named moricitrin A.

Figure 20. Experimental and calculated ECD spectra of compound 3 in MeOH, a and b
represent the model configurations of each compound

3.3.4. Moricitrin B
Compound 4 was obtained as brown amorphous powder, with an optical rotation of [α]22D 8.0 (c 0.05, MeOH). Its molecular formula was determined as C36H34O12, based on the HRESIMS
peak at m/z 657.1954 [M - H]- (calcd for 657.1967) and 1H and 13C NMR data (Table 1). Compound
4 was found also to be a symmetrical dineolignan that nominally showed half the actual numbers
of protons and carbons in its NMR spectra. It was determined as a 3, 3'-bisdemethylpinoresinol
derivative expanded with two phenylpropanoid groups. The observation of two sets of alkoxy
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signals contributed to this deduction. One set of signals at δC 87.0 (C-7, 7'), 55.4 (C-8, 8') and 72.7
(C-9, 9'), and δH 4.67 (H-7, 7'), 3.06 (H-8, 8'), and 4.19 and 3.81 (H-9a, 9'a and 9b, 9'b) suggested a
furofuran-type unit, and another set of signals at δC 77.6 (C-7", 7'"), 79.9 (C-8", 8'") and 62.1 (C9", 9'"), and δH 4.79 (H-7", 7'"), 3.98 (H-8", 8'"), and 3.65 and 3.45 (H-9"a, 9'"a and 9"b, 9'"b)
suggested a 1,4-benzodioxane-type moiety. Also, the

13

C NMR spectrum of 4 showed a pair of

adjacent chemical shifts at δC 144.4 (C-3, 3') and 144.8 (C-4, 4'), rather than δC 144.4 and 145.2 as
present in compound 3, suggesting a different connection of the two phenylpropanoid groups in
compound 4. The adjacent signals were consistent with the signals of C-3' and C-4' in princepin
(124), suggesting that the two dihydroxy-phenyl groups are located on the same side of the
molecule as C-4 and C-4', while the two hydroxymethyl groups are near to C-3 and C-3'. These
assignments were confirmed by HMBC (optimized coupling constant = 3 Hz) correlations between
H-7" and C-4, H-7'" and C-4', H-9"b (δ 3.45) and C-3, and H-9'"b (δ 3.45) and C-3' (Figure 21). All
the signals were assigned with the assistance of HSQC, COSY and HMBC NMR spectra.

Figure 21. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 4

Similar to compound 3, the trans relationships of H-7" and H-8", and H-7'" and H-8'" in
compound 4 were also determined based on the large coupling constant 7.9 Hz for both J7",8" and
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J 7'",8'", and the ROESY correlations between H-7/H-8 and H-7"/H-8", and H-7'/H-8' and H-7'"/H8'" were not detectable due to the long distance between these two sets of steric centers (6.8-7.7 Å,
Figure 22).

proton
H-7 to H-7"
H-7 to H-8"
H-8 to H-7"
H-8 to H-8"

distance
7.7 Å
6.8 Å
7.6 Å
7.3 Å

4
Figure 22. Distances between protons of steric centers for compounds 4 (energy minimized by
MM2 force field)

Among the four possible configurations, 4a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S), 4a' (7R,
8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R), 4b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R) and 4b' (7R, 8S, 7'R,
8'S, 7"S, 8"S, 7'"S, 8'"S), the ECD spectra for 4a and 4b were calculated. The experimental data
showed inverse Cotton effects with 4b (Figure 23). Thus, the structure of compound 4, named
moricitrin B, was established as a novel dineolignan with the same configuration with 4b', namely,
(7R,8S,7'R,8'S,7"S,8"S,7'"S,8'"S)-7,9':7',9:4,7":4',7'"-tetraepoxy-3,8":3',8'"-bisoxy-8,8'dineolignan-3",4",9",3'",4'",9'"-hexaol.
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Figure 23. Experimental and calculated ECD spectra of compound 4 in MeOH, a and b
represent the model configurations of each compound
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CHAPTER 4 Evaluation of Inhibitory Activities
From the raw extract of noni fruits to the final mixture (F-3-2-2) containing compounds 14, bioactive fractions were traced by inhibition assay against bacterial β-glucuronidase. Once
purified 1-4 were obtained, their individual inhibitory activities were evaluated to confirm if they
are the bioactive contributors to noni fruits. In the small intestine, there are also other important
enzymes like α-amylase, α-glucosidase and pancreatic lipase that are responsible for the digestion
of carbohydrates and triglycerides (127). Inhibition on these digestive enzymes may introduce
additional adverse gastrointestinal (GI) effects. Therefore, compounds 1-4 were examined further
for inhibitory activities against these enzymes to determine whether they are specific inhibitors
against bacterial β-glucuronidase with minimal GI side effects.
4.1.

Inhibitory Assays on Enzymes

4.1.1. Enzymes and Reagents
All enzymes used in this study, including β-glucuronidase from Escherichia coli (500 kU),
porcine pancreatic α-amylase (type VI-B), rat intestinal acetone powder, and pancreatic lipase
(type VI-S), were purchased from Sigma-Aldrich (St. Louis, MO, USA). The substrates 4-methyl
umbelliferyl-β-D-glucuronide hydrate, p-nitrophenyl-α- D-glucopyranoside (pNPG), and 4-methyl
umbelliferyl oleate (4-MU oleate) were obtained from Sigma-Aldrich, potato starch powder was
from Fisher Scientific (Fair Lawn, NJ, USA). Dinitrosalicylic acid reagent (DNS) from SigmaAldrich (St. Louis, MO, USA) acted as an indicator for α-amylase assay. Acarbose (Alfa Aesar,
Ward Hill, MA, USA), D-saccharic acid 1,4-lactone monohydrate (DSA, Sigma-Aldrich, St. Louis,
MO, USA), and orlistat (Sigma-Aldrich, St. Louis, MO, USA) were used as positive controls. The
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absorbance and fluorescence of inhibitory assays were measured in EnSpire multimode plate
reader (PerkinElmer, Waltham, MA, USA)
4.1.2. Bacterial β-Glucuronidase Assay
The inhibitory activities against bacterial β-glucuronidase were measured using black 96well microplates (42). Lyophilized samples were dissolved in 50% DMSO at various concentration
levels. A portion (1.5 µL) of each was transferred into a well, followed by addition of 60 µL of βglucuronidase (6.25 U/mL). The mixture was incubated for 5 min at room temperature, then added
with 40 µL of 4-methyl umbelliferyl-β-

D-glucuronide

hydrate (312.5 µM). After further

incubation of 30 min at 37 °C, the fluorescence values were measured at an excitation wavelength
of 355 nm and an emission wavelength of 460 nm. The results are expressed as percent inhibition
compared with solvent control, and DSA was used as positive control. IC50 values were calculated
based on inhibition percentages of series dilutions.
4.1.3. α-Amylase Assay
The α-amylase inhibitory activities were performed based on a previously established
method with small modifications (128). The samples and α-amylase (4 U/mL) were mixed and
incubated at room temperature for 5 min, then the substrate 0.5% potato starch solution was added
and incubated for 3 min at 37 °C. After addition of DNS reagent and reaction of 10 min at 90 °C,
25 µL of the cooled reaction mixture were loaded onto a 96-well plate and diluted with distilled
water. The absorbance was measured at 540 nm, and the results are expressed as percent inhibition
compared with solvent control, with acarbose as positive control.
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4.1.4. α-Glucosidase Assay
Rat α-glucosidase was used to evaluate inhibitory activities (128). The enzyme was
extracted from rat intestinal acetone powder with 0.1 M potassium phosphate buffer (pH 6.8). The
samples and α-glucosidase (0.025 g/mL) were incubated at 37 °C for 3 min, then 4 mM pNPG
were added and incubated for additional 30 min. The released p-nitrophenol from pNPG was
measured at 405 nm, which was inversely related to the sample’s inhibition level. The results are
expressed as percent inhibition compared with solvent control, with acarbose as positive control.
4.1.5. Pancreatic Lipase Assay
The enzyme inhibition was determined by measuring the released 4-methylumbelliferone
from 4-MU oleate (128). In brief, the samples and lipase (50 U/mL) were mixed with the substrate
4-MU oleate (0.1 mM), and incubated for 30 min at 37 °C. The fluorescence was measured at
excitation of 355 nm and emission of 460 nm. The results are expressed as percent inhibition
compared with solvent control, and orlistat (5 µg/mL) was used as positive control.
4.1.6. Data Analysis
Data from the bioactivity assays are reported as means ± SD, with the statistics analysis
performed using SPSS for Windows (version 25, 2017, IBM). IC50 values were calculated by a
probit procedure, and the statistical significance between groups was compared by one-way
ANOVA and the Tukey’s test (p < 0.05 or 0.01).
4.2.

Specific Inhibition Against Bacterial β-Glucuronidase
As shown in Table 7, the active compounds 1-4 exhibited potent inhibition against bacterial

β-glucuronidase, with IC50 values ranging from 0.62 to 6.91 µM. Their activities were 3.5 to 39.5-
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fold more potent than the positive control DSA, which gave an IC50 of 24.30 µM. It is also worth
noting that the isolated natural dineolignans 3 and 4 were more active against β-glucuronidase than
several synthesized novel inhibitors with IC50 values ranging from 1.7 to 4.8 µM (42). These results
may lead to new applications for the bioactive components of M. citrifolia (noni). As a nutritional
agent (52, 55), noni fruits could be developed into a safe and readily available dietary source to
more effectively prevent irinotecan-induced diarrhea than those synthesized compounds by more
potently inhibiting bacterial β-glucuronidase.
Table 7. Inhibitory Activities against Bacterial β-Glucuronidase
compound

IC50a (µM) ± SD

1

6.91 ± 0.16e

2

4.02 ± 0.06d

3

0.62 ± 0.01c

4

0.95 ± 0.01c

DSAb

24.30 ± 0.80f

a

IC50 values in µM, and SD represents standard deviation (n = 3). b DSA (D-saccharic acid 1,4lactone monohydrate) was used as positive control. Different letters (c-f) represent significant
differences with p < 0.01.

Interestingly, the dineolignans (compounds 3 and 4) showed an order of magnitude more
potent inhibition than the sesquineolignans (compounds 1 and 2), suggesting a strong structureactivity relationship. Bacterial β-glucuronidase has a loop that is absent in human β-glucuronidase,
and selective inhibitors exert their activity by binding to the overlapping loops at the tetramer
interface of the enzyme (22, 33). Compared to the sesquineolignans (1 and 2), the dineolignans (3
and 4) possess larger molecular sizes and more number of active hydroxy groups, which may
facilitate their binding to the active sites of the enzyme. Although sharing a similar skeleton,
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compound 1 showed more potent β-glucuronidase inhibitory activity than compound 2, and the
activity of compound 3 was also greater than that of compound 4, suggesting that their activities
are also influenced by the substitution variations of hydroxypropenyl and dihydroxyphenyl groups.
The results should provide valuable insights for searching for more effective inhibitors in the future.
4.3.

Inhibition on Digestive Enzymes
As shown in Figure 24A, all the compounds showed no or weak effects on intestinal α-

amylase. At the concentrations of 0.1 and 0.5 mg/mL, none of them exhibited significant inhibition.
When the concentration was increased to 1.0 mg/mL, compounds 2 (2.02 mM), 3 (1.52 mM) and
4 (1.52 mM) showed weak inhibition on α-amylase (the highest inhibition was 21%) compared to
the positive control acarbose, which resulted in 94% inhibition at 10 µg/mL (0.02 mM). Similar to
α-amylase, α-glucosidase was only minimally inhibited by compounds 1-4 at concentrations up to
1 mg/mL (Figure 24B). The highest inhibition of only 12% was from compound 1 at 1.0 mg/mL
(2.02 mM), while acarbose showed 80% inhibitory activity at 0.02 mM. Figure 24C shows that
compounds 1-4 exerted modest inhibition on lipase. At 0.1 mg/mL, all compounds exhibited
inhibition of less than 56%, and their activities increased in the order from 1 to 4. Up to 1.0 mg/mL,
they reached similar suppression values ranging from 85% to 93%, which were close to orlistat
(96%). However, at this inhibition level, 1 (2.02 mM) and 2 (2.02 mM) were at a concentration
level 200 times that of orlistat [0.01 mM (5 µg/mL)], while 3 (1.52 mM) and 4 (1.52 mM) were at
a concentration 152 times that of orlistat (0.01 mM). Therefore, the inhibition of compounds 1-4
on lipase was relatively weak versus the positive control used.
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Figure 24. Inhibitory effects of compounds 1-4 against α-amylase (A), α-glucosidase (B) and
pancreatic lipase (C).
Acarbose (10 µg/mL) and orlistat (5 µg/mL) were used as positive controls. C1-4 represent
compounds 1-4. The vertical bars represent the standard deviation (n = 3) for each data point,
and different letters represent significant differences (p < 0.05).
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CHAPTER 5 Discussion
5.1.

Bioassay-guided Isolation
Chemical constituents of natural resources are often more complex than expected in

structural types and numbers. There are no fixed processes to do extraction and isolation for those
constituents. However, the countless combinations of isolation processes are greatly decided by
the purposes of specific projects. To characterize chemical constituents of rarely or newly studied
natural materials, a systematic isolation is often performed to obtain as many compounds as
possible. Isolation of specific type of constituents needs to be guided by their unique chemical
properties. For instance, the basic property and selective reaction with Dragendroff’s reagent can
be used to guide the isolation of alkaloids. Bioassay-guided isolation has been widely used for
digging out active leads from chemical mixtures, such as paclitaxel from Taxus brevifolia and
camptothecin from Camptotheca acuminata, they were successfully discovered following target
bioactive assay (1). The aim of this project is to find out active compounds alleviating irinotecaninduced delayed diarrhea, thus the procedure was started with the method establishment of
appropriate in vitro biological assay (129). The diarrhea is caused by the intestinal SN-38 that is
primarily produced by bacterial β-glucuronidase. Therefore, inhibitory assay against bacterial βglucuronidase was established to trace active compounds from extracts of noni fruits.
During the isolation process, it is notable that activity of an extract or fraction is tested
negative or weak doesn’t mean that it is not worth further investigation. The principle of “like
dissolves like” concludes that polar/ionic solvents dissolve polar/ionic solutes and non-polar
solvents dissolve non-polar solutes. Selection of extraction solvents greatly impact on what
constituents can be obtained from the same natural material. Therefore, it is necessary to change
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solvents or adjust ratio of solvent combination to obtain bioactive extractions in some cases. A
famous example is the discovery of artemisinin (Qinghaosu). The success is attributed to the
change of extract solvent from hot water to low-temperature ethyl ether by Tu Youyou who was
awarded Nobel Prizes in 2015 (130, 131). 50% aqueous acetone was used to extract noni fruit
powder in this project. It is a good solvent mixture to dissolve both nonpolar and polar substances,
which ensured the chemical diversity and inclusion of active compounds for noni fruits extract.
The weak activities of some fractions may be caused by relatively lower concentration of active
components, which can be enhanced by enriching active compounds. As seen in this project, the
raw extract of noni fruits showed only about 50% inhibition against bacterial β-glucuronidase at
0.125 mg/mL. Along with continuous separation that get rid of inactive components, the inhibitory
activities of refined fractions were increased up to 90%. Eventually, the strong inhibitors,
compounds 1-4, were acquired with the assistance of bioassay. However, in some opposite cases,
high activity of an extraction is a result of synergistic effects of low active components, which may
turn out losing active targets after further separation (132, 133). This should be considered when
using bioassay-guided isolation.
5.2.

Structure Elucidations
Based on the characteristics of compounds 1-4, the commonly shared 1,4-benzodioxane

moiety makes it challenging to elucidate their structures. Firstly, the two oxygen atoms impede the
informative HMBC correlations across the1,4-dioxane ring, which was also observed in the
reported compounds, such as isoamericanin A, americanol A, isoamericanol A, princepin,
isoperincepin, isoamericanol B1, B2, C1, and C2 (124), haedoxancoside A (134), and
obovatalignan A (135). To determine the locations of hydroxymethyl and dihydroxy-phenyl groups,
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the parameters of HMBC experiment can be optimized to achieve longer correlations (124). As
shown in this investigation, the expected HMBC correlations across the 1,4-dioxane ring were
presented after optimizing the proton-carbon coupling constant to 3 Hz. Secondly, the rigid plane
of 1,4-benzodioxane separates the two steric centers of compounds 1-4 with theoretical distances
in the range 6.2-8.0 Å (Figure 13, 16, 19 and 22). NOESY and ROESY correlations could be
observed for protons separated typically by less than 5 Å (136, 137), thus, they are not applicable
to establish the relative configurations for this type of molecules.
ECD computation is often based on confirmed relative configurations, but also available
for known possible relative configurations (138). Since the relative configurations were not
decided, each of compounds 1-4 has eight configurations theoretically. Because the hydroxymethyl
and dihydroxy-phenyl groups in each compound were assigned as trans substitutions, the numbers
of possible configurations were reduced to four. Just based on these four possibilities, their
absolute configurations were established through ECD calculation.
5.3.

In vitro Study
In this study, purified compounds from noni fruits showed potent and specific inhibition

against β-glucuronidase of Escherichia coli. However, there are still several essential steps needed
to extrapolate this promising work to the clinical application alleviating irinotecan-induced
delayed diarrhea.
We conclude the inhibitory selectivity of our compounds 1-4 based on their none or weak
inhibition against digestive enzymes. However, their inhibition on other lysosomal βglucuronidases of mammalian host may also need to be investigated. For instance, human βglucuronidase has been considered as reliable biomarker for diagnosing diseases like different
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cancers, and potential target for the development of anti-inflammatory and anticancer drugs (139).
Wallace et al. elucidated the crystal structure of the first bacterial β-glucuronidase from E. coli,
and found that it has a 45% of sequence similarity with human β-glucuronidase (33). We don’t
expect that our compounds 1-4 have side effects on glycosyl hydrolysis in host tissues and
biofluids because of this similarity. It can be verified by measuring their inhibition against bovine
liver β-glucuronidase, modified E. coli β-glucuronidase or other lysosomal β-glucuronidases (33).
Wallace et al. also revealed that β-glucuronidase of E. coli possesses a unique “bacterial loop” of
17 residues that is widely distributed in other human gut microbiota, while lacked in human βglucuronidase (33). Molecular docking study are used to investigate structure-activity relationship
(SAR) between inhibitors and human β-glucuronidase (140-142). The inhibitory selectivity of
compounds 1-4 can also be predicted through docking study that shows binding interactions of
compounds with the key active sites of the bacterial loop.
In another investigation by Wallace et al., β-glucuronidases from Streptococcus agalactiae
and Clostridium perfringens of Firmicutes, Escherichia coli of Proteobacterium and Bacteroides
fragilis of Bacteroidetes were compared together (11). These orthologous enzymes shared very
similar structures but showed different catalytic properties and were variously inhibited by
designed compounds. It suggests that our selective inhibitors against E. coli β-glucuronidase may
also interact very differently with enzymes of other bacteria, which result in different net effect on
the overall deconjugation of SN-38G. Therefore, we need to measure inhibition of our compounds
on the enzyme of as more representative bacteria as possible, to evaluate their potential impacts
on overall microbial β-glucuronidases. In addition, we need the most powerful data of animal and
clinical experiments to convince our hypothesis that compounds 1-4 can alleviate irinotecaninduced delayed diarrhea.
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5.4.

In vivo Study
Balb/cJ mice are often used in cancer studies because of their tendency to develop different

kinds of tumor (Figure 25). For instance, tumor-bearing Balb/cJ mice have been utilized for the
discovery of irinotecan (CPT-11) (143). Unlike human β-glucuronidase, research on bacterial βglucuronidase inhibitors is a relatively new field that was firstly reported in 2010, and few of these
inhibitors have reached animal experiment (139). In both investigations of Wallace et al. and
Cheng et al., healthy Balb/cJ female mice were used to evaluate bacterial β-glucuronidase
inhibitors’ effects in alleviating irinotecan-induced delayed diarrhea (33, 44). Therefore, healthy
Balb/cJ model could also be used to assess our specific inhibitors. The experimental mice can be
assigned into four groups and treated with 1) solvent of irinotecan intraperitoneally (i.p.) + solvent
of inhibitor via oral gavage, 2) irinotecan + solvent of inhibitor, 3) solvent of irinotecan + inhibitor,
4) irinotecan + inhibitor. The dose of inhibitor needs to be calculated carefully according to
literature and preliminary experiment.

Figure 25. Balb/cJ mouse

Besides of inhibitors’ effects on delayed diarrhea, their influence on irinotecan’s anticancer
ability is another important consideration need to be figured out by animal experiment. Gupta et
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al. showed that there was an obvious secondary peak of serum SN-38 level in patients infused
intravenously with irinotecan (17). Kehrer et al. found that SN-38 could be transported across the
membrane of colonic Caco-2 monolayers from apical to basolateral (144). These observations
indicate that intestinal SN-38 may be reabsorbed into plasma to exert anticancer effect. In other
words, inhibition of bacterial β-glucuronidase may reduce plasma SN-38 level and subsequently
impair the therapeutic efficacy of irinotecan. As shown in the research on inhibitor pyrazolo[4,3c]quinoline derivative (TCH-3562) by Cheng et al. (44), monitoring the plasma pharmacokinetics
of SN-38 is a practicable approach to learn the influence of our specific inhibitors on irinotecan’s
efficacy. In addition, the inhibitors’ influence on the growth of gut bacteria can be determined by
incubating our inhibitors with live bacteria, such as E. coli cells (44). It can also be examined by
profiling entire gut microbial composition using16S rRNA sequencing (145).
Up to date, there has no clinical trial been reported for inhibitors of E. coli β-glucuronidase
in alleviating irinotecan-induced delayed diarrhea. Nevertheless, as mentioned above, some
synthesized compounds have been shown strong inhibition on the enzyme. Animal studies have
demonstrated their capacities in reducing delayed diarrhea and maintaining efficacy of irinotecan,
while with limited impact on normal gut microbial community and the growth of epithelial cells.
These researches have established a basic framework to develop inhibitors of bacterial βglucuronidase. Our compounds 1-4 possess potent and specific inhibition against the enzyme, and
with minimized side effects on the intestinal digestion, which have been a solid foundation for
further research and development. Moreover, our specific inhibitors are discovered from noni
fruits, which is a widely distributed and dietary safe natural resource. Therefore, the noni fruits
and their active compounds are promising to be developed as a dietary supplement or therapeutic
approach to alleviate the irinotecan-induced delayed diarrhea.
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APPENDIX
HRESIMS (Figure A1-A4), and 1H,

13

C, COSY, HSQC, HMBC and ROESY NMR spectra for

(7S,8S,7'R,8'R)-isoamericanol B (1, Figure A5-A11), americanol B (2, Figure A12-A18),
moricitrin A (3, Figure A19-A25), and moricitrin B (4, Figure A26-A32).
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Figure A1. HRESIMS spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A2. HRESIMS spectrum of americanol B (2)
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Figure A3. HRESIMS spectrum of moricitrin A (3)
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Figure A4. HRESIMS spectrum of moricitrin B (4)
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Figure A5. 1H NMR (500 MHz, CD3OD) spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A6. 13C NMR (125 MHz, CD3OD) spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A7. COSY (CD3OD) spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A8. HSQC (CD3OD) spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A9. HMBC (CD3OD) spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A5. HMBC (600 MHz, CD3OD, coupling constant = 3 Hz) spectrum of (7S,8S,7'R,8'R)isoamericanol B (1)
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Figure A6. ROESY (CD3OD) spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1)
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Figure A7. 1H NMR (500 MHz, CD3OD) spectrum of americanol B (2)
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Figure A8. 13C NMR (125 MHz, CD3OD) spectrum of americanol B (2)
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Figure A9. COSY (CD3OD) spectrum of americanol B (2)
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Figure A10. HSQC (CD3OD) spectrum of americanol B (2)
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Figure A11. HMBC (CD3OD) spectrum of americanol B (2)
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Figure A12. HMBC (600 MHz, CD3OD, coupling constant = 3 Hz) spectrum of americanol B
(2)
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Figure A18. ROESY (CD3OD) spectrum of americanol B (2)
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Figure A19. 1H NMR (500 MHz, CD3OD) spectrum of moricitrin A (3)
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Figure A20. 13C NMR (125 MHz, CD3OD) spectrum of moricitrin A (3)
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Figure A13. COSY (CD3OD) spectrum of moricitrin A (3)
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Figure A14. HSQC (CD3OD) spectrum of moricitrin A (3)
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Figure A15. HMBC (CD3OD) spectrum of moricitrin A (3)
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Figure A16. HMBC (600 MHz, CD3OD, coupling constant = 3 Hz) spectrum of moricitrin A (3)
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Figure A17. ROESY (CD3OD) spectrum of moricitrin A (3)
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Figure A18. 1H NMR (500 MHz, CD3OD) spectrum of moricitrin B (4)
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Figure A19. 13C NMR (125 MHz, CD3OD) spectrum of moricitrin B (4)
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Figure A28. COSY (CD3OD) spectrum of moricitrin B (4)
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Figure A29. HSQC (CD3OD) spectrum of moricitrin B (4)
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Figure A30. HMBC (CD3OD) spectrum of moricitrin B (4)
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Figure A31. HMBC (600 MHz, CD3OD, coupling constant = 3 Hz) spectrum of moricitrin B (4)
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Figure A32. ROESY (CD3OD) spectrum of moricitrin B (4)
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ABSTRACT
DEVELOPMENT OF SPECIFIC NATURAL BACTERIAL BETA-GLUCURONIDASE
INHIBITORS FOR REDUCING IRINOTECAN-ASSOCIATED DIARRHEA
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ABSTRACT:
Irinotecan is a derived compound from the plant alkaloid camptothecin (CPT). It
specifically inhibits eukaryotic DNA enzyme topoisomerase I. Irinotecan was approved by the
FDA as the second-line therapy for metastatic colon or rectal cancer in 1996. However, one of its
leading side effects is diarrhea. It has been reported that up to 88% of treated patients were
suffering from diarrhea and 31% of cases with grade 3 or 4 diarrhea. Irinotecan is metabolized into
SN-38G in the liver, then SN-38G is excreted to the intestinal tract and deconjugated back to SN38 by bacterial β-glucuronidase. The free SN-38 in the gut leads to the delayed diarrhea by
damaging the intestinal mucosa. Therefore, selectively inhibiting bacterial β-glucuronidase has
been an attractive strategy to alleviate irinotecan-induced delayed diarrhea. We preliminarily
screened about 50 extracts and found that an extract of noni (Morinda citrifolia) fruits showed
potent inhibitory activity on gut bacterial β-glucuronidase. In this study, four bacterial β-
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glucuronidase inhibitors were obtained following bioactive assay-guided isolation, including two
sesquineolignans, (7S,8S,7'R,8'R)-isoamericanol B (1) and americanol B (2), and two dineolignans,
moricitrin A (3) and B (4). Compounds 2-4 are new, and the absolute configuration of compound
1 was determined for the first time. Their chemical structures were elucidated through HRESIMS
and NMR spectra, and their absolute configurations were established via the comparison of the
experimental and calculated electronic circular dichroism (ECD) spectra. These compounds
showed potent inhibition against gut bacterial β-glucuronidase with IC50 values in the range 0.626.91 µM. The inhibition presented specificity for β-glucuronidase as all the compounds showed
no or weak effects on digestive enzymes such as α-amylase, α-glucosidase and lipase, suggesting
that their gastrointestinal side effects could be minimized. These specific inhibitors as naturally
occurring dietary compounds may be developed as promising candidates to alleviate irinotecaninduced diarrhea.
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